Polyvinyl Butyrate Nanoparticles as Butyrate Donors for Colitis Treatment. 2021

Yunmei Mu, and Yusuke Kinashi, and Jinting Li, and Takuma Yoshikawa, and Akihiro Kishimura, and Mitsuru Tanaka, and Toshiro Matsui, and Takeshi Mori, and Koji Hase, and Yoshiki Katayama
Graduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan.

Butyrate has been attracting attention for the suppression of inflammatory bowel disease (IBD). However, clinical trials of butyrate for IBD treatment have resulted in controversial outcomes, likely owing to the adverse effect of butyrate on the intestinal epithelium that was observed at high butyrate concentrations. Herein, we propose polyvinyl butyrate (PVBu) nanoparticles (NPs) as butyrate donors for delivery to the lower part of the intestine for the treatment of colitis. The PVBu NPs suppressed the inflammatory activation of macrophages in vitro, although sodium butyrate inversely further activated macrophages. Oral administration of NPs did not change the luminal concentration of free butyrate; however, NPs showed a therapeutic effect on a colitis mouse model. In addition, incorporation of vitamin D3 into the NPs enhanced the therapeutic effect on colitis. Hence, PVBu NPs are a promising therapeutic for IBD treatment, not only as a butyrate donor but also as a carrier for hydrophobic drugs like vitamin D3.

UI MeSH Term Description Entries
D008297 Male Males
D008422 Materials Testing The testing of materials and devices, especially those used for PROSTHESES AND IMPLANTS; SUTURES; TISSUE ADHESIVES; etc., for hardness, strength, durability, safety, efficacy, and biocompatibility. Biocompatibility Testing,Biocompatible Materials Testing,Hemocompatibility Testing,Testing, Biocompatible Materials,Testing, Hemocompatible Materials,Hemocompatibility Testings,Hemocompatible Materials Testing,Materials Testing, Biocompatible,Materials Testing, Hemocompatible,Testing, Biocompatibility,Testing, Hemocompatibility,Testing, Materials,Testings, Biocompatibility
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D010316 Particle Size Relating to the size of solids. Particle Sizes,Size, Particle,Sizes, Particle
D011145 Polyvinyls POLYMERS derived from the monomer VINYL COMPOUNDS. Polyvinyl
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003092 Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER. Colitides
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D000067996 RAW 264.7 Cells A transformed macrophage cell line isolated from ASCITES of mice infected with ABELSON MURINE LEUKEMIA VIRUS. RAW 264.7 Cell Line,264.7 Cell, RAW,264.7 Cells, RAW,Cell, RAW 264.7,Cells, RAW 264.7,RAW 264.7 Cell

Related Publications

Yunmei Mu, and Yusuke Kinashi, and Jinting Li, and Takuma Yoshikawa, and Akihiro Kishimura, and Mitsuru Tanaka, and Toshiro Matsui, and Takeshi Mori, and Koji Hase, and Yoshiki Katayama
May 2021, Polymers,
Yunmei Mu, and Yusuke Kinashi, and Jinting Li, and Takuma Yoshikawa, and Akihiro Kishimura, and Mitsuru Tanaka, and Toshiro Matsui, and Takeshi Mori, and Koji Hase, and Yoshiki Katayama
June 2022, Science China. Life sciences,
Yunmei Mu, and Yusuke Kinashi, and Jinting Li, and Takuma Yoshikawa, and Akihiro Kishimura, and Mitsuru Tanaka, and Toshiro Matsui, and Takeshi Mori, and Koji Hase, and Yoshiki Katayama
January 1969, Zhurnal eksperimental'noi i klinicheskoi meditsiny,
Yunmei Mu, and Yusuke Kinashi, and Jinting Li, and Takuma Yoshikawa, and Akihiro Kishimura, and Mitsuru Tanaka, and Toshiro Matsui, and Takeshi Mori, and Koji Hase, and Yoshiki Katayama
December 2010, Biomacromolecules,
Yunmei Mu, and Yusuke Kinashi, and Jinting Li, and Takuma Yoshikawa, and Akihiro Kishimura, and Mitsuru Tanaka, and Toshiro Matsui, and Takeshi Mori, and Koji Hase, and Yoshiki Katayama
September 2015, Journal of the mechanical behavior of biomedical materials,
Yunmei Mu, and Yusuke Kinashi, and Jinting Li, and Takuma Yoshikawa, and Akihiro Kishimura, and Mitsuru Tanaka, and Toshiro Matsui, and Takeshi Mori, and Koji Hase, and Yoshiki Katayama
October 2020, Acta biomaterialia,
Yunmei Mu, and Yusuke Kinashi, and Jinting Li, and Takuma Yoshikawa, and Akihiro Kishimura, and Mitsuru Tanaka, and Toshiro Matsui, and Takeshi Mori, and Koji Hase, and Yoshiki Katayama
October 1996, Alimentary pharmacology & therapeutics,
Yunmei Mu, and Yusuke Kinashi, and Jinting Li, and Takuma Yoshikawa, and Akihiro Kishimura, and Mitsuru Tanaka, and Toshiro Matsui, and Takeshi Mori, and Koji Hase, and Yoshiki Katayama
January 2018, RSC advances,
Yunmei Mu, and Yusuke Kinashi, and Jinting Li, and Takuma Yoshikawa, and Akihiro Kishimura, and Mitsuru Tanaka, and Toshiro Matsui, and Takeshi Mori, and Koji Hase, and Yoshiki Katayama
May 2020, Nanomedicine (London, England),
Yunmei Mu, and Yusuke Kinashi, and Jinting Li, and Takuma Yoshikawa, and Akihiro Kishimura, and Mitsuru Tanaka, and Toshiro Matsui, and Takeshi Mori, and Koji Hase, and Yoshiki Katayama
February 1995, Digestive diseases and sciences,
Copied contents to your clipboard!